BioTuesdays

Tag - ATNM

Actinium Pharma Logo
Markets

Cantor starts Actinium Pharma at OW; PT $20

Cantor Fitzgerald launched coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with an “outperform” rating and $20 price target. The stock closed at $7.51 on Sept. 7. Actinium is a clinical-stage biopharmaceutical...

September 8, 2022
Markets

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

August 8, 2019
Feature

Actinium gearing up for pivotal trial in second half

By Len Zehr Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute...

March 24, 2015